NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

NewAmsterdam Pharma Company N.V. achieved a significant regulatory achievement on September 21 when the European Commission approved Ubeslo and Evlarco, marking the first global approvals for these cholesterol-reduction treatments. Ubeslo contains 10 mg of obicetrapib, while Evlarco combines 10 mg of obicetrapib with 10 mg of ezetimibe. Both medicines are intended for adults managing primary high cholesterol or mixed lipid disorders.
The treatments target low-density lipoprotein cholesterol red